Last reviewed · How we verify

Abciximab + UFH — Competitive Intelligence Brief

Abciximab + UFH (Abciximab + UFH) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycoprotein IIb/IIIa inhibitor (in combination with anticoagulant). Area: Cardiovascular.

marketed Glycoprotein IIb/IIIa inhibitor (in combination with anticoagulant) Platelet glycoprotein IIb/IIIa receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Abciximab + UFH (Abciximab + UFH) — Deutsches Herzzentrum Muenchen. Abciximab is a monoclonal antibody that blocks platelet glycoprotein IIb/IIIa receptors to prevent platelet aggregation, combined with unfractionated heparin (UFH) for anticoagulation during percutaneous coronary intervention.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Abciximab + UFH TARGET Abciximab + UFH Deutsches Herzzentrum Muenchen marketed Glycoprotein IIb/IIIa inhibitor (in combination with anticoagulant) Platelet glycoprotein IIb/IIIa receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycoprotein IIb/IIIa inhibitor (in combination with anticoagulant) class)

  1. Deutsches Herzzentrum Muenchen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Abciximab + UFH — Competitive Intelligence Brief. https://druglandscape.com/ci/abciximab-ufh. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: